The corona pandemic has ensured that the term "mRNA" is now also known to a large public beyond laboratories and lecture halls. However, the molecule is much more than an important component of a ...

The 3rd mRNA Process Development and Manufacturing Summit returns to Boston this September, poised to help you implement high throughput process development, scale-up mRNA synthesis and purification, ...

RNA-based therapeutics are transforming medicine, but scaling production efficiently remains a challenge, particularly the cost-intensive in vitro transcription (IVT) step. Join this webinar to ...

Imagine you're a scientist, tasked with the challenge of rapidly producing large quantities of high-quality messenger RNA (mRNA) for use in cutting-edge medical treatments. Where do you even start?

In an era where viral outbreaks can escalate into global pandemics with alarming speed, the ability to quickly develop new vaccines has become crucial. However, the speed of vaccine production is ...

This article provides an overview of solutions to address key challenges facing vaccine developers or CDMOs wishing to build their own commercial-scale mRNA production facilities. Messenger RNA (mRNA) ...

From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...

eTheRNA Immunotherapies, a clinical-stage company developing mRNA-based cancer immunotherapies from its unique TriMix platform, announces it has been awarded a €1 million industrial R&D Projects Grant ...

Unique solutions are required to protect inherently unstable messenger RNA. Oligonucleotide drug substances generally are unstable at room temperature, and some are also degraded in the presence of ...